MRD in AML

The Role of New Techniques

Maria Teresa Voso, Tiziana Ottone, Serena Lavorgna, Adriano Venditti, Luca Maurillo, Francesco Lo-Coco, Francesco Buccisano

Research output: Contribution to journalReview article

Abstract

In the context of precision medicine, assessment of minimal residual disease (MRD) has been used in acute myeloid leukemia (AML) to direct individual treatment programs, including allogeneic stem cell transplantation in patients at high-risk of relapse. One of the limits of this approach has been in the past the paucity of AML markers suitable for MRD assessment. Recently, the number of biomarkers has increased, due to the identification of highly specific leukemia-associated immunophenotypes by multicolor flow-cytometry, and of rare mutated gene sequences by digital droplet PCR, or next-generation sequencing (NGS). In addition, NGS allowed unraveling of clonal heterogeneity, present in AML at initial diagnosis or developing during treatment, which influences reliability of specific biomarkers, that may be unstable during the disease course. The technological advances have increased the application of MRD-based strategies to a significantly higher number of AML patients, and the information deriving from MRD assessment has been used to design individual post-remission protocols and pre-emptive treatments in patients with sub-clinical relapse. This led to the definition of MRD-negative complete remission as outcome definition in the recently published European Leukemianet MRD guidelines. In this review, we summarized the principles of modern technologies and their clinical applications for MRD detection in AML patients, according to the specific leukemic markers.

Original languageEnglish
Article number655
JournalFrontiers in Oncology
Volume9
DOIs
Publication statusPublished - Jul 23 2019

Fingerprint

Residual Neoplasm
Acute Myeloid Leukemia
Biomarkers
Recurrence
Precision Medicine
Stem Cell Transplantation
Flow Cytometry
Leukemia
Therapeutics
Guidelines
Technology
Polymerase Chain Reaction
Genes

Keywords

  • AML
  • digital droplet PCR
  • MRD
  • multiparametric flow-cytometry
  • NGS

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Voso, M. T., Ottone, T., Lavorgna, S., Venditti, A., Maurillo, L., Lo-Coco, F., & Buccisano, F. (2019). MRD in AML: The Role of New Techniques. Frontiers in Oncology, 9, [655]. https://doi.org/10.3389/fonc.2019.00655

MRD in AML : The Role of New Techniques. / Voso, Maria Teresa; Ottone, Tiziana; Lavorgna, Serena; Venditti, Adriano; Maurillo, Luca; Lo-Coco, Francesco; Buccisano, Francesco.

In: Frontiers in Oncology, Vol. 9, 655, 23.07.2019.

Research output: Contribution to journalReview article

Voso, MT, Ottone, T, Lavorgna, S, Venditti, A, Maurillo, L, Lo-Coco, F & Buccisano, F 2019, 'MRD in AML: The Role of New Techniques', Frontiers in Oncology, vol. 9, 655. https://doi.org/10.3389/fonc.2019.00655
Voso MT, Ottone T, Lavorgna S, Venditti A, Maurillo L, Lo-Coco F et al. MRD in AML: The Role of New Techniques. Frontiers in Oncology. 2019 Jul 23;9. 655. https://doi.org/10.3389/fonc.2019.00655
Voso, Maria Teresa ; Ottone, Tiziana ; Lavorgna, Serena ; Venditti, Adriano ; Maurillo, Luca ; Lo-Coco, Francesco ; Buccisano, Francesco. / MRD in AML : The Role of New Techniques. In: Frontiers in Oncology. 2019 ; Vol. 9.
@article{2eeb3bea43fd438383ede2c35c80367b,
title = "MRD in AML: The Role of New Techniques",
abstract = "In the context of precision medicine, assessment of minimal residual disease (MRD) has been used in acute myeloid leukemia (AML) to direct individual treatment programs, including allogeneic stem cell transplantation in patients at high-risk of relapse. One of the limits of this approach has been in the past the paucity of AML markers suitable for MRD assessment. Recently, the number of biomarkers has increased, due to the identification of highly specific leukemia-associated immunophenotypes by multicolor flow-cytometry, and of rare mutated gene sequences by digital droplet PCR, or next-generation sequencing (NGS). In addition, NGS allowed unraveling of clonal heterogeneity, present in AML at initial diagnosis or developing during treatment, which influences reliability of specific biomarkers, that may be unstable during the disease course. The technological advances have increased the application of MRD-based strategies to a significantly higher number of AML patients, and the information deriving from MRD assessment has been used to design individual post-remission protocols and pre-emptive treatments in patients with sub-clinical relapse. This led to the definition of MRD-negative complete remission as outcome definition in the recently published European Leukemianet MRD guidelines. In this review, we summarized the principles of modern technologies and their clinical applications for MRD detection in AML patients, according to the specific leukemic markers.",
keywords = "AML, digital droplet PCR, MRD, multiparametric flow-cytometry, NGS",
author = "Voso, {Maria Teresa} and Tiziana Ottone and Serena Lavorgna and Adriano Venditti and Luca Maurillo and Francesco Lo-Coco and Francesco Buccisano",
year = "2019",
month = "7",
day = "23",
doi = "10.3389/fonc.2019.00655",
language = "English",
volume = "9",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - MRD in AML

T2 - The Role of New Techniques

AU - Voso, Maria Teresa

AU - Ottone, Tiziana

AU - Lavorgna, Serena

AU - Venditti, Adriano

AU - Maurillo, Luca

AU - Lo-Coco, Francesco

AU - Buccisano, Francesco

PY - 2019/7/23

Y1 - 2019/7/23

N2 - In the context of precision medicine, assessment of minimal residual disease (MRD) has been used in acute myeloid leukemia (AML) to direct individual treatment programs, including allogeneic stem cell transplantation in patients at high-risk of relapse. One of the limits of this approach has been in the past the paucity of AML markers suitable for MRD assessment. Recently, the number of biomarkers has increased, due to the identification of highly specific leukemia-associated immunophenotypes by multicolor flow-cytometry, and of rare mutated gene sequences by digital droplet PCR, or next-generation sequencing (NGS). In addition, NGS allowed unraveling of clonal heterogeneity, present in AML at initial diagnosis or developing during treatment, which influences reliability of specific biomarkers, that may be unstable during the disease course. The technological advances have increased the application of MRD-based strategies to a significantly higher number of AML patients, and the information deriving from MRD assessment has been used to design individual post-remission protocols and pre-emptive treatments in patients with sub-clinical relapse. This led to the definition of MRD-negative complete remission as outcome definition in the recently published European Leukemianet MRD guidelines. In this review, we summarized the principles of modern technologies and their clinical applications for MRD detection in AML patients, according to the specific leukemic markers.

AB - In the context of precision medicine, assessment of minimal residual disease (MRD) has been used in acute myeloid leukemia (AML) to direct individual treatment programs, including allogeneic stem cell transplantation in patients at high-risk of relapse. One of the limits of this approach has been in the past the paucity of AML markers suitable for MRD assessment. Recently, the number of biomarkers has increased, due to the identification of highly specific leukemia-associated immunophenotypes by multicolor flow-cytometry, and of rare mutated gene sequences by digital droplet PCR, or next-generation sequencing (NGS). In addition, NGS allowed unraveling of clonal heterogeneity, present in AML at initial diagnosis or developing during treatment, which influences reliability of specific biomarkers, that may be unstable during the disease course. The technological advances have increased the application of MRD-based strategies to a significantly higher number of AML patients, and the information deriving from MRD assessment has been used to design individual post-remission protocols and pre-emptive treatments in patients with sub-clinical relapse. This led to the definition of MRD-negative complete remission as outcome definition in the recently published European Leukemianet MRD guidelines. In this review, we summarized the principles of modern technologies and their clinical applications for MRD detection in AML patients, according to the specific leukemic markers.

KW - AML

KW - digital droplet PCR

KW - MRD

KW - multiparametric flow-cytometry

KW - NGS

UR - http://www.scopus.com/inward/record.url?scp=85072124394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072124394&partnerID=8YFLogxK

U2 - 10.3389/fonc.2019.00655

DO - 10.3389/fonc.2019.00655

M3 - Review article

VL - 9

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - 655

ER -